The American Lung Association and Myogen Announce Pulmonary Arterial Hypertension Educational Partnership

The American Lung Association and Myogen, Inc. (Nasdaq:
MYOG) today announced that they will collaborate on a new public
awareness initiative to educate the public about pulmonary arterial
hypertension (PAH), a progressive and life-threatening disease that
affects an estimated 200,000 patients worldwide.
   The multi-year educational partnership will be launched this fall
and will include a variety of outreach activities, all designed to
better inform the public about signs and symptoms as well as treatment
options for PAH. There is no known cure for PAH, but early diagnosis
and treatment can reduce symptoms, improve quality of life, slow the
progression of the disease and extend patients' lives.
   "We are pleased to collaborate with Myogen on this important
educational partnership," said Dr. Norman H. Edelman, Chief Medical
Officer for the American Lung Association. "Our combined expertise in
this area and commitment to improving patients' lives will hopefully
allow us to increase awareness and knowledge of this serious disease.
Ultimately, we hope this education collaboration will benefit
patients."
   "The American Lung Association is the nation's oldest voluntary
health organization, and their dedication to the prevention of lung
disease and to the promotion of lung health is unmatched," said J.
William Freytag, President and Chief Executive Officer of Myogen. "By
partnering with such a respected organization, we can expand the
collective knowledge base about PAH and employ their nationwide
network and resources to broaden awareness of this disease."
   PAH is a highly debilitating disease characterized by severe
constriction of the blood vessels in the lungs leading to very high
pulmonary arterial pressures. These high pressures make it difficult
for the heart to pump blood through the lungs to be oxygenated.
Patients with PAH suffer from extreme shortness of breath and severe
limitations of physical exertion as the heart struggles to pump
against these high pressures. Patients with advanced stages of PAH
have a poor prognosis and highly compromised quality of life. If
untreated, they have a mean life expectancy of two to five years from
diagnosis. PAH can occur with no known underlying cause, or it can
occur secondary to diseases such as connective tissue disease,
congenital heart defects, cirrhosis of the liver and human
immunodeficiency virus (HIV) infection.
   Therapies currently used for the treatment of PAH include
anticoagulants; diuretics; calcium channel blockers; digoxin;
prostacyclins; phosphodiesterase inhibitors and endothelin receptor
antagonists.

   About the American Lung Association

   Beginning our second century, the American Lung Association is the
leading organization working to prevent lung disease and promote lung
health. Lung disease death rates continue to increase while other
leading causes of death have declined. The American Lung Association
funds vital research on the causes of and treatments for lung disease.
With the generous support of the public, the American Lung Association
is "Improving life, one breath at a time." For more information about
the American Lung Association or to support the work it does, call
1-800-LUNG-USA (1-800-586-4872) or log on to www.lungusa.org.

   About Myogen

   Myogen has two product candidates in late-stage clinical
development: ambrisentan for the treatment of patients with pulmonary
arterial hypertension (PAH) and darusentan for the treatment of
patients with resistant hypertension. Myogen and GlaxoSmithKline have
entered into a global PAH collaboration in which Myogen has marketing
and distribution rights to GlaxoSmithKline's Flolan(R) (epoprostenol
sodium) for Injection in the United States and GlaxoSmithKline has
licensed ambrisentan from Myogen for all territories outside of the
United States, where Myogen retains exclusive rights. Myogen also
conducts a target and drug discovery research program focused on the
development of disease-modifying drugs for the treatment of chronic
heart failure and related cardiovascular disorders. Please visit
Myogen's website at www.myogen.com.